Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
NC1-H5254 | Human | Human NCAM-1 / CD56 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified) |
|
||
NC1-M52H4 | Mouse | Mouse NCAM-1 / CD56 Protein, His Tag |
|
||
NC1-HF2H5 | Human | FITC-Labeled Human NCAM-1 / CD56 Protein, His Tag |
|
||
NC1-HF256 | Human | FITC-Labeled Human NCAM-1 / CD56 Protein, Fc Tag |
|
||
NC1-H82E3 | Human | Biotinylated Human NCAM-1 / CD56 Protein, His,Avitag™ (MALS verified) |
|
||
NC1-H5253 | Human | Human NCAM-1 / CD56 Protein, Fc Tag (MALS verified) |
|
||
NC1-H5223 | Human | Human NCAM-1 / CD56 Protein, His Tag (MALS verified) |
|
Immobilized Anti-NCAM-1 Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human NCAM-1, Fc Tag (Cat. No. NC1-HF256) with a linear range of 0.08-0.625 μg/mL (QC tested).
The purity of Human NCAM-1 Protein, Llama IgG2b Fc Tag (Cat. No. NC1-H5254) is more than 90% and the molecular weight of this protein is around 245-285 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
This web search service is supported by Google Inc.